<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0413066</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2830</journal-id>
<journal-id journal-id-type="nlm-ta">Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell</journal-id>
<journal-title-group>
<journal-title>Cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">0092-8674</issn>
<issn pub-type="epub">1097-4172</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30901547</article-id>
<article-id pub-id-type="pmc">6531313</article-id>
<article-id pub-id-type="doi">10.1016/j.cell.2019.02.003</article-id>
<article-id pub-id-type="manuscript">NIHMS1523829</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genomic medicine -- progress, pitfalls, and promise</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shendure</surname>
<given-names>Jay</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Findlay</surname>
<given-names>Gregory M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snyder</surname>
<given-names>Matthew W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">‡</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Genome Sciences, University of Washington, Seattle, WA, USA, 98195</aff>
<aff id="A2"><label>2</label>Howard Hughes Medical Institute, Seattle, WA, USA, 98195</aff>
<aff id="A3"><label>3</label>Brotman Baty Institute for Precision Medicine, Seattle, WA, USA, 98195</aff>
<author-notes>
<fn fn-type="current-aff" id="FN1">
<label>‡</label>
<p id="P1">Current affiliation: Bellwether Bio, Inc., Seattle, WA, USA, 98104</p>
</fn>
<corresp id="CR1">Correspondence: <email>shendure@uw.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P91">Conflicts of Interest</p>
<p id="P92">JS has financial interests in companies working on subjects related to genomic medicine, including Adaptive Biotechnologies, Bellwether Bio, Camp4 Therapeutics, Cambridge Epigenetix, GenePeeks, Maze Therapeutics, Nanostring, Phase Genomics, and Stratos Genomics. His lab has an unfunded collaborative research agreement with Illumina. MS is a founder and employee of Bellwether Bio.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>177</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>57</lpage>
<!--elocation-id from pubmed: 10.1016/j.cell.2019.02.003-->
<abstract id="ABS1">
<title>Summary</title>
<p id="P2">In the wake of the Human Genome Project (HGP), strong expectations were set for the timeline and impact of genomics on medicine -- an anticipated transformation in the diagnosis, treatment and prevention of disease. In this review, we take stock of the nascent field of genomic medicine. In what areas, if any, is genomics delivering on this promise, or is the path to success clear? Where are we falling short, and why? What have been the unanticipated developments? Overall, we argue that the optimism surrounding the transformational potential of genomics on medicine remains justified, albeit with a considerably different form and timescale than originally projected. We also argue that the field needs to pivot “back to basics”, as understanding the entirety of the genotype to phenotype equation is a likely prerequisite for delivering on the full potential of the human genome to advance the human condition.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>